Related Experiment Video
Updated: Aug 15, 2026
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
The challenge of treating node-positive prostate cancer. An approach to resolving the questions
1Fox Chase Cancer Center/University of Pennsylvania, Philadelphia.
Background:
Prostate cancer commonly presents with positive pelvic lymph nodes. The appropriate management of patients with prostate cancer is controversial and no satisfactory randomized trials have been conducted.
Methods:
Available literature was reviewed, particularly concerning long-term survival after primary surgery or radiation therapy with or without adjuvant androgen deprivation.
Results:
With surgery, 10-40% of patients with low volume nodal disease are 10-year, no evidence of disease (NED) survivors and with radiation, 10-20% of node-positive patients are free of failure at 10 years. Few studies include past treatment and prostate specific antigen (PSA) data. It also appears that androgen deprivation may improve survival after surgery.
Conclusions:
At least 40,000 patients of all clinical stages will have node-positive prostate cancer in 1992. A careful systematic investigation by prospective trial of the available treatment options is needed to establish the optimal management of these prostate cancers.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistent Cancers